A Randomized, Double-Blind, Phase 3 Comparison of Platinum-Based Therapy with TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Sponsor: GSK/Tesaro
Participating sites:
- UZ Leuven, Leuven
- AZ Sint-Jan Brugge, Brugge
- CHU St. Pierre, Bruxelles
- AZ Klina, Brasschaat
